Researcher's microdissection device hits the market to fight cancer
The AvanSci Bio team is (front to back) Rob Parry, Katherine Geiersbach, Mark Herrmann and Nils Adey. Photo Credit: Courtesy of Technology Venture Development
A new device designed to more effectively produce DNA samples for genetic testing from slide-mounted tissue samples is better equipped than most models on the market to help in the diagnosis and treatment of cancer. Its University of Utah inventors say the microdissection device is an effective and reasonably priced method for removing tissue samples from microscope slides. The samples are used for genetic testing, so precision is essential. The impact could be substantial because genetic testing is becoming more popular in the fight against cancer, and so the demand for efficient dissection tools is growing.
The related Salt Lake City startup company, AvanSci Bio, is just now selling the new device, called the MESO-1. The company was formed in 2011 and has attracted significant funding including a $50,000 grant from the U, more than $500,000 from private investors, and most recently, a $213,000 grant from the federal Small Business Innovation Research (SBIR) program. Additional funding is on the horizon.
Their device addresses a need in clinical laboratories for a slide microdissection system that is semi-automated, precise and convenient to use for the pathologist, said Beth Drees, a manager at the Us Technology Commercialization Office (TCO), which administers the Us intellectual property and assisted AvanSci Bio in many ways. A growing number of molecular tests require that specific cells of interest, such as tumor cells, be dissected out from slide-mounted tissue samples.
The MESO-1 consists of three basic parts: an instrument that resembles a small milling machine equipped with a joy stick and digital microscope for controlling the milling process; a specialized consumable mill bit called the xScisor; and computer software for annotating images and pinpointing a tissue section to be collected. The xScisor is one of the most unique components of the device and mills the tissue from the slide surface while simultaneously dispensing and aspirating fluid to recover the displaced tissue fragments. The tissue fragments are then recovered for further testing.
One major user group targeted is laboratories performing genetic testing to detect mutations in cancer. The industry standard is to use a scalpel to scrape part of a tumor off a slide. This method is inexpensive and works for many samples, but it falls short when precision is required. A laser method also exists to collect precise samples, but those instruments can cost up to $500,000.
MESO-1 falls in between these two competing methods by providing a more accurate sample than scraping slides by hand, while being much less expensive than laser methods. AvanSci Bio expects to sell its device for a base price of $20,000. The name for MESO-1 suggests the middle ground it fills in the marketplace meso means middle.
Co-inventor Katherine Geiersbach, M.D., assistant professor in the Us Department of Pathology, first identified the need for the device while working in molecular oncology at Associated Regional and University Pathologists (ARUP), the Us national reference laboratory that performs laboratory testing for University Health care and for other hospital systems across the country. She was frustrated by the lack of a method that was more precise than hand-scraping while more convenient than the laser method.
In the clinical testing arena, we frequently need greater accuracy than we can achieve with a scalpel, but LCM (laser capture microdissection) is not a practical solution for most labs, says Geiersbach. In addition to greater accuracy, our device fills the need for maintaining digital records of the dissection process. It captures pre- and post-dissection images and creates an electronic report for each sample.
AvanSci Bio believes their device will be helpful to as many as 500 clinical labs, including ARUP, and 2,500 research labs. The company projects a 20 percent annual market-growth rate leading to substantial demand for its device due to its unique capabilities and the rising popularity of genetic testing. In addition, it anticipates developing more versions of the device for different levels of accuracy and higher volumes of testing.
While Geiersbach identified the need for the device, provided pathology and biochemical materials and oversight, and was closely involved with the development process, other members of AvanSci Bio and ARUP executed a diverse array of tasks.
Getting the microdissection device ready for market was a collaborative effort. ARUPs Mark Herrmann played an integral role in its development by providing the mechanical engineering expertise to design and build the MESO-1 instrument and the xScisor consumable. AvanSci Bio CSO, Nils Adey, Ph.D., conceived and developed early prototypes of the xScisor and led the biochemical testing and validation efforts. Rob Parry, an engineer, entrepreneur and AvanSci Bio CEO, oversaw the development process and daily operations of AvanSci Bio, and was intimately involved with all elements of the instrument and software design that make up the MESO-1 system.
Provided by University of Utah
- A miniature device with a big impact Feb 27, 2012 | not rated yet | 0
- New micro-device could change drug testing Mar 20, 2012 | not rated yet | 0
- Detecting cancer with the prick of a finger (w/ Video) Nov 16, 2010 | not rated yet | 0
- Bringing lab-on-a-chip to a surgery near you Dec 02, 2008 | not rated yet | 0
- Faster, cheaper Mercury test could provide answers for China Oct 07, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
11 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...
Cancer 2 hours ago | not rated yet | 0
Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.
Cancer 3 hours ago | not rated yet | 0 |
Frequent heartburn was positively associated with cancers of the throat and vocal cord among nonsmokers and nondrinkers, and the use of antacids, but not prescription medications, had a protective effect, according to data ...
Cancer 3 hours ago | not rated yet | 0
Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.
Cancer 5 hours ago | 5 / 5 (1) | 0
An anti-cancer drug reverses memory deficits in an Alzheimer's disease mouse model, University of Pittsburgh Graduate School of Public Health researchers confirm in the journal Science.
55 minutes ago | not rated yet | 0 |
Can economic incentives such as gift cards, T-shirts, and time off from work motivate members of the public to increase their donations of blood?
1 hour ago | not rated yet | 0 |
Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as the sensation of ...
1 hour ago | 5 / 5 (1) | 0 |
Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.
1 hour ago | not rated yet | 0 |
A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...
2 hours ago | 4.8 / 5 (4) | 0 |
Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...
1 hour ago | not rated yet | 0 |